
Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.

Your AI-Trained Oncology Knowledge Connection!


Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.

Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.

The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.

Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.

Hussein Tawbi, MD, PhD, presents the case of a 67-year-old woman with stage IV melanoma and shared his initial impressions.

Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.

Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.

Hussein Tawbi, MD, PhD, emphasizes that combination immunotherapies offer higher efficacy than single agent PD-1 inhibitors for metastatic melanoma; however, patient characteristics guide the choice of treatment regimen, with toxicities playing a key role.

The RELATIVITY-047 trial evaluated relatlimab and nivolumab versus nivolumab alone in patients with metastatic melanoma, revealing improved progression-free survival, while PDL-1 status wasn't predictive of outcomes.

Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.

Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.

Hussein Tawbi, MD, PhD, highlights the importance of BRAF mutations and LDH levels in diagnosing patients with metastatic melanoma and guiding treatment.

Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.

Hussein Tawbi, MD, PhD, presents the case of a 78-year-old man with metastatic melanoma and shares his initial impressions.

Hussein Tawbi, MD, PhD closes the discussion by outlining current unmet needs in the unresectable metastatic melanoma treatment landscape.

Discussion centered around planning for, managing, and overcoming adverse effects in the first-line systemic therapy setting for melanoma.

Thoughtful comments from Dr Hussein Tawbi on setting first-line treatment goals and typical treatment responses in patients with unresectable or metastatic melanoma.

Clinical insights regarding the treatment of patients with BRAF-mutated metastatic melanoma presenting with symptomatic/asymptomatic brain metastases.

Revisiting the patient case study, Dr Hussein Tawbi shares how he might approach systemic first-line treatment in this situation, with a focus on limiting drug toxicity.

Data-driven clinical insights concerning the selection of effective first-line treatment options for patients with BRAF-mutated metastatic melanoma, with a focus on the DREAMseq trial.

Subject matter expert provides a comprehensive overview of available first-line therapy options for patients with unresectable or metastatic melanoma and a BRAF mutation.

Hussein Tawbi, MD, PhD reviews a case study of a 47-year-old woman with BRAF-mutated metastatic melanoma and discusses his approach to workup, including biomarker testing, for patients with the disease.

Hussein A. Tawbi, MD, PhD, discusses why melanoma responds so well to immunotherapy.

Published: November 8th 2023 | Updated:

Published: January 30th 2023 | Updated:

Published: November 22nd 2023 | Updated:

Published: November 29th 2023 | Updated:

Published: November 29th 2023 | Updated:

Published: February 13th 2023 | Updated: